Tag Treatment Action Group Inc

What it reported doing in 2024

See schedule ohiv programaccording to the july 2025 unaids global AIDS report, "40.8 million [37.0 million-45.6 million] people globally were living with HIV in 2024. 1.3 million [1 million-1.7 million] people became newly infected with HIV in 2024. 630 000 [490 000-820 000] people died from AIDS-related illnesses in 2024. 31.6 million people [27.8-32.9 million] were accessing antiretroviral therapy in 2024. 91.4 million [73.4 million-116.4 million] people have become infected with HIV since the start of the epidemic. 44.1 million [37.6 million-53.4 million] people have died from AIDS-related illnesses since the start of the epidemic." according to the u.s. Centers for disease control and prevention (cdc) 2025 update, there were over 39,000 people newly diagnosed with HIV, almost 4,500 HIV-related deaths, and over 1,132,000 americans living with HIV by the end of 2023.tag's HIV program works to maximize equitable, affordable access to the tools, services, policies, and approaches to prevention and care that are essential for the goal of ending the HIV epidemic domestically and globally. Advocacy focused on ending the epidemic (ete, or ehe) is at the core of the HIV program's work, from driving the nation's first ete initiative in New York to leading the act now: end AIDS (anea) coalition's support for partners in heavily burdened jurisdictions in the southern u.s. Tag's HIV and policy teams tackle issues around drug pricing and equitable access to emerging biomedical interventions; funding for evidence-based HIV programming; access to healthcare; and policies that promote safe, inclusive environments that are free of stigma and discrimination for people to seek prevention and care for HIV and related infections, including sexually transmitted infections.tag's HIV program leads research activism and promotes community engagement to ensure that people living with HIV everywhere have more options including, ultimately, a safe and effective HIV vaccine and a cure that are scalable, affordable, and can be used worldwide. Tag's HIV program recognizes that even the most effective existing prevention and treatment interventions have shortcomings. To this end, tag's basic science, vaccine and cure project tracks the antiretroviral, cure, immune-based therapy, and biomedical prevention pipelines and publishes annual reports summarizing their current status. Tag also plays a vital leadership role in basic science, vaccines, and cure advocacy, participating in community advisory boards and administering an email discussion listserv for stakeholders in HIV cure and immune-based therapy research. In 2024, tag contributed to the new u.s. National institutes of health (nih) strategic plan for HIV and HIV-related research, covering 2026-2030. During the planning process, tag's HIV project staff served on the nih office of AIDS research basic biomedical and preclinical research taskforce. Tag's HIV cure-related clinical trials website listing, updated monthly to provide information on studies and their results, is widely cited in scientific papers and in conference presentations. The HIV program also advocates for appropriate interventions for people who, despite HIV treatment, still have poor immune system recovery. Central to this work is ensuring legislators and policy makers understand the ongoing needs for research and HIV-related funding, and how important it is to make decisions based on scientific evidence.tag staff continue to participate as members of the prep in black america coalition, a network of advocates working to increase equitable access and uptake of pre-exposure prophylaxis for HIV prevention, which in april 2024 hosted a research-focused pre-conference ahead of the nmac biomedical HIV prevention summit. Tag also continues to lead and co-organize community engagement activities on HIV cure research, including the annual pre-croi community HIV cure research workshop, and continues to maintain the only known database monitori

Financial Efficiency

• Mission deployment rate: 94.7%; rating input score 95
• Program expense ratio: 82.5%; rating input score 83
• Fundraising efficiency: $11.76 raised per $1 spent on fundraising; rating input score 43; 43rd percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: 1 of 6 controls in place; rating input score 17
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Pass
• Foreign activity oversight: 1 of 8 controls in place; rating input score 12
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Fail
  • Conducts field audits: Fail
  • May suspend future funding: Fail
  • Requires financial reports: Fail
  • Conducts site visits: Fail
  • Requires grant agreements: Fail
  • May require repayment: Fail
• Grant itemization coverage: 100%; rating input score 100; 72nd percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -14.5%; rating input score 10; 10th percentile among comparable filings
• Total-asset coverage ratio: 0.94; rating input score 35; 35th percentile among comparable filings
• Liabilities to assets ratio: 0.19; rating input score 45; 45th percentile among comparable filings
• Officer compensation ratio: 22.4%; rating input score 10; 10th percentile among comparable filings

Growth

• Program expense growth: 4.6% per year; rating input score 100; 37th percentile among comparable filings
• Revenue growth: 5.1% per year; rating input score 100; 42nd percentile among comparable filings
• Asset growth: 4.1% per year; rating input score 100; 30th percentile among comparable filings